美关税从10%上调至15%推升贸易不确定性 欧洲股市下跌 诺和诺德减肥药23%减重效果不及礼来股价重挫

Group 1 - European stock markets declined due to rising uncertainty over U.S. tariff policies, with Danish pharmaceutical company Novo Nordisk experiencing a significant drop in stock price [1] - The U.S. Supreme Court ruled on February 20 that tariffs imposed by the Trump administration under the International Emergency Economic Powers Act were illegal, leading to an increase in the global import tariff rate from 10% to 15% [1] - The European Commission stated that the current situation is detrimental to achieving fair transatlantic trade and investment, demanding transparency from the U.S. regarding future actions [1] Group 2 - Novo Nordisk's weight loss drug CagriSema failed to meet its primary endpoint in the REDEFINE4 clinical trial, showing a 23% weight loss effect, which is less effective compared to similar products from Eli Lilly [2] - The failure of the trial may have short-term implications for Novo Nordisk's commercialization prospects in the weight loss sector, intensifying competition in the market [2] - The fluctuating U.S. tariff policies pose potential cost pressures for European export companies, further suppressing overall market risk appetite in Europe [2]